Clinical Liver Disease10.1002/cld.26201214114-116Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver diseaseKathleen E. Corey, Raj Vuppalanchi,
Liver Transplantation10.1002/lt.250032018242166-170Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantationZobair M. Younossi,
Clinical Liver Disease10.1002/cld.66201214129-130Management of nonalcoholic fatty liver disease in childrenJean P. Molleston,
Clinical Liver Disease10.1002/cld.65201214104-107Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkersMazen Noureddin, Rohit Loomba,
Nonalcoholic Fatty Liver Disease - An Update10.5772/intechopen.880412019Introductory Chapter: Nonalcoholic Fatty Liver Disease - What Should We Know?Emad Hamdy Gad, Yasmin Kamel
Clinical and Molecular Hepatology10.3350/cmh.2022.0442202329Suppls86-s102Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyen,,
Clinical and Molecular Hepatology10.3350/cmh.2023.00662023292384-389Implications of comorbidities in nonalcoholic fatty liver diseaseSherlot Juan Song, Vincent Wai-Sun Wong,,
Digestive and Liver Disease10.1016/j.dld.2018.11.084201951e27Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization (HCRU) and costs: results from Italian administrative databasesG. Marchesini, J. Ting, S. Saragoni, L. Degli Esposti, A.B. Ozbay, S. Petta,
Nonalcoholic Fatty Liver Disease - An Update10.5772/intechopen.857802019The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular CarcinomaZaki A. Sherif
Clinical Liver Disease10.1002/cld.27201214112-113Natural history of nonalcoholic fatty liver diseaseRohini Mehta, Zobair M. Younossi,